HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Vorinostat, an HDAC inhibitor, promotes degradation of HIF-1 indirectly through HDAC inhibition and is in clinical use to treat cutaneous T cell lymphoma [152,153].